Hit ID Platform

Banner Image

At the core of a successful drug discovery is a high-quality chemical library. A fit-for-purpose drug discovery library is not a random collection of compounds, but a collection of carefully curated chemistry that is designed to cover the diversity of drug-like chemistry space, and provide tractable starting points for medicinal chemistry optimisation.

This project will build on a national framework to provide Australian drug discovery organisations access to a comprehensive Hit ID platform that includes:

  • a fit for purpose drug discovery library (up to 300,000 compounds);
  • an ultra-high throughput screening facility;
  • fragment-based drug design capability;
  • a state of the art software platform for in silico drug discovery.

Outcomes (FY2020):

  • New storage infrastructure and 310,000 compound bank to allow fast screening of compounds to determine new target drug formulations. 
  • 6 screenings have already been performed since the project completion.

Visit Cancer Therapeutics CRC for more details.

Twitter: cancercrcGRIDD_GU

LinkedIn: Cancer Therapeutics CRC

Consortium lead

Cancer Therapeutics CRC Pty Ltd (CTx)

Consortium members

UniQuest, Walter and Eliza Hall Institute (WEHI), Children's Cancer Institute (CCI), Griffith University / Compounds Australia

MTPConnect grant $1,100,000
Industry contribution $1,384,290
Project duration August 2017 - June 2019 (Completed)
Contact Brendon Monahan, Cancer CRC - brendon@cancercrc.com